Featured Publications
Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study
Kauke-Navarro M, Panayi AC, Formica R, Marty F, Parikh N, Foroutanjazi S, Safi AF, Mardini S, Razonable RR, Morelon E, Gelb B, Rodriguez E, Lassus P, Pomahac B. Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. Transplantation 2022, 106: 2031-2043. PMID: 35389381, DOI: 10.1097/tp.0000000000004132.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCytomegalovirusCytomegalovirus InfectionsHumansRetrospective StudiesValganciclovirVascularized Composite AllotransplantationViremiaConceptsRetrospective cohort studyAntiviral prophylaxisCohort studyComposite allotransplantationInternational multicenter retrospective cohort studyMulticenter retrospective cohort studyCMV-related complicationsFirst year posttransplantHigh-risk transplantsMore rejection episodesHigh-risk groupFacial Vascularized Composite AllotransplantationAllograft-related complicationsVascularized Composite AllotransplantationPaucity of dataAllograft lossCMV diseaseCMV viremiaCytomegalovirus serostatusR serostatusRejection episodesCMV infectionPrompt treatmentActive surveillancePatients
2023
Vascularized Composite Allograft Versus Prosthetic for Reconstruction After Facial and Hand Trauma
Noel O, Dumbrava M, Daoud D, Kammien A, Kauke-Navarro M, Pomahac B, Colen D. Vascularized Composite Allograft Versus Prosthetic for Reconstruction After Facial and Hand Trauma. Annals Of Plastic Surgery 2023, 92: 100-105. PMID: 37962243, DOI: 10.1097/sap.0000000000003731.Peer-Reviewed Original ResearchMeSH KeywordsComposite Tissue AllograftsFacial InjuriesHumansPlastic Surgery ProceduresUpper ExtremityVascularized Composite AllotransplantationConceptsHand traumaHand/upper extremityLong-term outcomesUpper extremity traumaDifferent reconstructive optionsUse of prosthesesExtremity traumaBenefit profileUpper extremityReconstructive optionsComposite allotransplantationFace traumaHand reconstructionTraumaClinical realityPrimary optionProsthesisPatientsVCANovel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchMeSH KeywordsGenetic EngineeringGraft RejectionHumansImmunosuppressive AgentsOrgan TransplantationTransplantation, HomologousVascularized Composite AllotransplantationConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical successCellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionHumansImmune ToleranceImmunosuppression TherapyTransplantation, HomologousVascularized Composite AllotransplantationConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesCorrelation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients
Kauke-Navarro M, Knoedler S, Panayi A, Knoedler L, Haller B, Parikh N, Huelsboemer L, Stoegner V, Kiefer J, Eisenhardt S, Azzi J, Pomahac B. Correlation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 83: 155-164. PMID: 37276734, DOI: 10.1016/j.bjps.2023.04.050.Peer-Reviewed Original ResearchBiomarkersGraft RejectionHumansRetrospective StudiesTransplantation, HomologousVascularized Composite AllotransplantationInsights from immunoproteomic profiling of a rejected full-face transplant
Lee C, Wang D, Kauke-Navarro M, Russell-Goldman E, Xu S, Mucciarone K, Sohrabi S, Lian C, Pomahac B, Murphy G. Insights from immunoproteomic profiling of a rejected full-face transplant. American Journal Of Transplantation 2023, 23: 1058-1061. PMID: 37037378, DOI: 10.1016/j.ajt.2023.04.008.Peer-Reviewed Original ResearchMeSH KeywordsComposite Tissue AllograftsFacial TransplantationGraft RejectionGraft SurvivalProteomicsVascularized Composite AllotransplantationConceptsVascularized Composite AllograftsT cellsChronic rejectionCD8-positive T cellsEffector T cellsFull face transplantArteriosclerotic alterationsIntragraft arteriesVCA rejectionGraft arteryAccelerated arteriosclerosisRecipient originPunch biopsyAtherogenic responseComposite allograftsImmunoproteomic profilingDioxygenase 1Target endotheliumArteryEndotheliumProteomic profilingPathway componentsCellsRejectionAllograftsTolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models
Huelsboemer L, Kauke-Navarro M, Reuter S, Stoegner V, Feldmann J, Hirsch T, Kueckelhaus M, Dermietzel A. Tolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models. Transplant International 2023, 36: 10955. PMID: 36846605, PMCID: PMC9946984, DOI: 10.3389/ti.2023.10955.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsComposite Tissue AllograftsGraft RejectionImmune ToleranceImmunosuppressive AgentsTransplantation, HomologousVascularized Composite AllotransplantationConceptsTolerance inductionLong-term effectsAnimal modelsImmune systemDonor-specific toleranceLong-term outcomesRecipient's immune systemPreclinical animal modelsNovel therapeutic strategiesPre-clinical studiesVascularized Composite AllotransplantationChronic rejectionImmunosuppressive protocolsTransplant recipientsAllograft rejectionOrgan dysfunctionPreclinical modelsComposite allograftsTherapeutic strategiesComposite allotransplantationClinical practiceIS protocolClinical translationInductionReview article
2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionImmune TolerancePrecision MedicineT-Lymphocytes, RegulatoryVascularized Composite AllotransplantationConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerance
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGraft RejectionHumansImmunomodulationImmunosuppressive AgentsRatsSkinTacrolimusVascularized Composite AllotransplantationConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approachesDonor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool
Kauke M, Haug V, Obed D, Diehm Y, Tchiloemba B, Safi AF, Pomahac B. Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool. Plastic & Reconstructive Surgery 2021, 148: 194-202. PMID: 34181616, DOI: 10.1097/prs.0000000000008094.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCytomegalovirusCytomegalovirus InfectionsDonor SelectionFemaleHepacivirusHepatitis CHumansMaleMiddle AgedRetrospective StudiesTime FactorsVascularized Composite AllotransplantationWaiting ListsYoung AdultConceptsDonor poolHepatitis CUnited NetworkPotential donorsEpstein-Barr virus seropositivityCytomegalovirus-seropositive donorsUnderrepresented patient groupsOrgan Sharing databaseFacial Vascularized Composite AllotransplantationHigh-risk characteristicsVascularized Composite AllotransplantationActual wait timesAllotransplant patientsSeronegative patientsSeropositive donorsMost patientsAllotransplant recipientsPatient characteristicsRecipient matchingSharing databasePositive donorsPatient groupVirus seropositivityOrgan SharingOrgan donors
2020
Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation
Kauke-Navarro M, Tchiloemba B, Haug V, Kollar B, Diehm Y, Safi AF, Treister NS, Annino DJ, Marty FM, Lian CG, Murphy GF, Pomahac B. Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 1562-1571. PMID: 33376080, DOI: 10.1016/j.bjps.2020.11.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedComposite Tissue AllograftsFaceFemaleGraft RejectionHumansMaleMiddle AgedMouth MucosaNasal MucosaRetrospective StudiesVascularized Composite AllotransplantationConceptsNasal mucous membraneMucous membranesMucosal inflammationMucosal lesionsBanff gradeInflammatory mucosal lesionsUlceration/erosionRetrospective cohort studyClinico-pathologic variablesMucosal rejectionCohort studyCutaneous changesIndependent predictorsMucosal assessmentOral lesionsSkin rejectionSinonasal mucosaCommon lesionsMedical recordsUnivariate analysisCutaneous pathologyBuccal mucosaNasal vestibuleOral cavityComposite allotransplantationLocal immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsRatsSwineTacrolimusTreatment OutcomeVascularized Composite AllotransplantationConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategiesMucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review.
Kauke M, Safi AF, Zhegibe A, Haug V, Kollar B, Nelms L, Palmer WJ, Tchiloemba B, Lian CG, Murphy GF, Pomahac B. Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review. Transplantation 2020, 104: 2616-2624. PMID: 32053572, DOI: 10.1097/tp.0000000000003171.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiopsyComposite Tissue AllograftsFacial TransplantationFemaleGraft RejectionGraft SurvivalHumansMaleMiddle AgedMucous MembraneSkinSkin TransplantationTreatment OutcomeVascularized Composite AllotransplantationConceptsMucosal rejectionSystematic reviewRejection gradeMucosal biopsiesPatient managementComposite allotransplantationDiagnosis of rejectionFunction of patientsFacial Vascularized Composite AllotransplantationMeta-Analyses (PRISMA) guidelinesMEDLINE/PubMedPreferred Reporting ItemsVascularized Composite AllotransplantationPosttransplant periodBiopsy gradeSkin rejectionMucosa biopsiesAllograft skinAnimal studiesReporting ItemsBiopsyRejection processFacial allotransplantsMucosaTarget tissues
2019
MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study
Kollar B, Uffing A, Borges TJ, Shubin AV, Aoyama BT, Dagot C, Haug V, Kauke M, Safi AF, Talbot SG, Morelon E, Dakpe S, Pomahac B, Riella LV. MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study. Frontiers In Immunology 2019, 10: 2771. PMID: 31849957, PMCID: PMC6897344, DOI: 10.3389/fimmu.2019.02771.Peer-Reviewed Original ResearchMeSH KeywordsAdultAutoimmunityBiomarkersFemaleGraft RejectionHumansMaleMatrix Metalloproteinase 3Middle AgedPrognosisRetrospective StudiesROC CurveSeverity of Illness IndexSkin TransplantationVascularized Composite AllotransplantationConceptsMatrix metalloproteinase-3MMP3 levelsNon-invasive biomarkersTransplant recipientsAcute rejectionHealthy controlsComposite allotransplantationRejection stateCandidate non-invasive biomarkersUpper extremity transplant recipientsSerum samplesAntibody-mediated rejectionKidney transplant recipientsSeverity of rejectionPre-transplant levelsAutoimmune skin diseaseLongitudinal serum samplesSkin disease patientsVascularized Composite AllotransplantationMulticenter validation studyFace transplant recipientsLarger validation studiesClinical VCARejection episodesVCA patients